Key players in Long-Acting HIV Treatment
In the order our report profiles them, not ranked by sales. Each name opens the company's page with its public records.
| # | Company | Website | Our reports |
|---|---|---|---|
| 1 |  ViiV Healthcare |
viivhealthcare.com (opens in a new tab) | 66 reports |
| 2 |  Gilead Sciences, Inc. |
gilead.com (opens in a new tab) | 297 reports |
| 3 |  Johnson & Johnson |
jnj.com (opens in a new tab) | 2,376 reports |
| 4 |  Merck & Co., Inc. |
merck.com (opens in a new tab) | 1,320 reports |
Top trial sponsors in Long-Acting HIV Treatment
Companies leading the most active studies found with this market's trial search, worldwide (key players included).
- ViiV Healthcare 14 active trials on ClinicalTrials.gov (opens in a new tab)
- Gilead Sciences, Inc. 6 active trials on ClinicalTrials.gov (opens in a new tab)
Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Long-Acting HIV Treatment reports by place
Australia
Brazil
Canada
China
Ecuador
Egypt
France
Germany
Hong Kong
India
Italy
Japan
Kenya
Malaysia
Mexico
New Zealand
PhilippinesGet the full Long-Acting HIV Treatment report
Company profiles, market shares and strategies come with the full report, with researched size, forecast, growth and segments.
Key players are our report's research. Other companies and trial counts come from free public records, each with its source. Acuitas market figures are not published on this page.